Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

dti announces nominees for 2008 Science and Technology Awards
2008-10-03

 

At the announcement of the nominees for the 2008 dti Technology Awards were, from the left: Prof. Schalk Louw, Department of Zoology and Entomology, Mr Sipho Zikode, Deputy Director General at the Department of Trade and Industry (dti), Dr Romilla Maharaj, Executive Director: Human and Institutional Capacity Development at the National Research Foundation (NRF), and Mr Ephraim Baloyi, Director: Innovation and Technology at the dti.

Mr Michael Chung, master’s student in Plant Pathology, explaining some of the research conducted in the Centre for Plant Health Management (Cephma).

Prof. Schalk Louw, Department of Zoology and Entomology, and Mr Ephraim Baloyi, Director: Innovation and Technology at the dti in the Cephma laboratory.

   
dti announces nominees for 2008 Science and Technology Awards

The Department of Trade and Industry’s (dti) Deputy Director-General, Mr Sipho Zikode, yesterday announced the nominees for the 2008 dti Technology Awards which will take place on 30 and 31 October in Bloemfontein.

The purpose of these annual awards is to recognise those researchers, private institutions and students who performed well in terms of innovation and technology development, says Mr Ephraim Baloyi, Director: Innovation and Technology at the dti.

The awards are a combination of the Annual Awards of the different dti programmes supporting technology in industry. They are the Technology and Human Resources for Industry Programme (THRIP), administered by the National Research Foundation (NRF), the Support Programme for Industrial Innovation (SPII), administered by the Industrial Development Corporation, and seda Technology Programme (stp), administered by the Small Enterprise Development Agency.

The dti delegation also visited the laboratory of Prof. Schalk Louw of the UFS to view the work of this former dti Technology Awards recipient. Prof. Louw is a member of the UFS Centre for Plant Health Management (Cephma) team that won a 2007 Technology Award for groundbreaking research work on kenaf (a South African commercial fibre crop used, amongst others, in the automotive industry). The research of the Cephma team is supported by the NRF’s THRIP programme.

The awards are hosted in a different province each year to increase awareness around the dti’s technology support for researchers, small enterprises, large industries and business incubators.

Media Release
Issued by: Leonie Bolleurs
Tel: 051 401 2707
Cell: 083 645 5853
3 October 2008

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept